Crossref
Disarming myeloid resistance in CAR T therapy
Cancer Cell · 2025
DOI: 10.1016/j.ccell.2025.06.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2025. Verfasst von John M Warrington und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Section of Cellular Therapy, Washington University School of Medicine, St. Louis, MO, USA; Center for Gene and Cellular Immunot…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Myeloid Cells, Lymphoma, B-Cell. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Immunotherapy, AdoptiveReceptors, Chimeric AntigenMyeloid CellsLymphoma, B-CellT-LymphocytesHumansAntigens, CD19Receptors, Granulocyte-Macrophage Colony-Stimulating FactorReceptors, Antigen, T-CellAnimals
Substanzen
Receptors, Chimeric AntigenAntigens, CD19Receptors, Granulocyte-Macrophage Colony-Stimulating FactorReceptors, Antigen, T-Cell
Autor:innen und Institutionen
- Division of Oncology, Section of Cellular Therapy, Washington University School of Medicine, St. Louis, MO, USA; Center for Gene and Cellular Immunotherapy, Washington University School of Medicine, St. Louis, MO, USA.
- Division of Oncology, Section of Cellular Therapy, Washington University School of Medicine, St. Louis, MO, USA; Center for Gene and Cellular Immunotherapy, Washington University School of Medicine, St. Louis, MO, USA.…
Zitieren
APA
Warrington, J. M., & Singh, N. (2025). Disarming myeloid resistance in CAR T therapy. Cancer Cell. https://doi.org/10.1016/j.ccell.2025.06.003
Vancouver
Warrington JM, Singh N. Disarming myeloid resistance in CAR T therapy. Cancer Cell. 2025. doi:10.1016/j.ccell.2025.06.003
BibTeX
@article{Warrington2025,
author = {Warrington, John M and Singh, Nathan},
title = {Disarming myeloid resistance in CAR T therapy},
journal = {Cancer Cell},
year = {2025},
doi = {10.1016/j.ccell.2025.06.003}
}
EUVIMED